Dimitar Tcharaktchiev
Biographic Data
| ID | 9993287 |
|---|---|
| NAME | Dimitar Tcharaktchiev |
| GIVEN NAMES | Dimitar |
| FAMILY NAME | Tcharaktchiev |
| SIGNATURE | TCHARAKTCHIEV D |
| AFFILIATIONS | Medical University of Sofia |
| ORCID | 0000-0001-5765-840X |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
Budget cap and pay-back model to control spending on medicines
Central and Eastern European countries (CEEC) have among the highest rates of increase in healthcare expenditure. External reference pricing, generics and biologics price capping, regressive scale for price setting, health technology assessment (HTA), and positive drug lists for reimbursed medicines are among the variety of implemented cost-containment measures aimed at reducing and controlling the rising cost for pharmaceuticals. The aim of our …
New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria
Background: Acromegaly and its comorbidities affect the patients’ quality of life, each healthcare system and the society. This study aimed to evaluate clinical characteristics and treatment patterns and the economic burden of acromegaly. Materials and methods: All patients with acromegaly treated with expensive medicines and regularly followed up at the main expert clinical center for acromegaly in the country were included in this nationwide, r…
No prominent works on this page.
New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria
Background: Acromegaly and its comorbidities affect the patients’ quality of life, each healthcare system and the society. This study aimed to evaluate clinical characteristics and treatment patterns and the economic burden of acromegaly. Materials and methods: All patients with acromegaly treated with expensive medicines and regularly followed up at the main expert clinical center for acromegaly in the country were included in this nationwide, r…
Budget cap and pay-back model to control spending on medicines
Central and Eastern European countries (CEEC) have among the highest rates of increase in healthcare expenditure. External reference pricing, generics and biologics price capping, regressive scale for price setting, health technology assessment (HTA), and positive drug lists for reimbursed medicines are among the variety of implemented cost-containment measures aimed at reducing and controlling the rising cost for pharmaceuticals. The aim of our …
Environmental health (2 works) · Internal Medicine (2 works) · Medicine (2 works) · Acromegaly (1 work) · Actuarial science (1 work) · Adrenal and Paraganglionic Tumors (1 work) · Business (1 work) · Economic growth (1 work) · Economics (1 work) · Epidemiology (1 work)